DAFTAR PUSTAKA

1. Hudoyo A, Wibawanto A, Lutfi A, dkk. Pedoman Nasional Pelayanan Kedokteran : Kanker Paru. Kementrian Kesehatan Republik Indonesia. 2017. p. 7- 19
2. Sung, H., Ferlay, J., Soerjomataram, I., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A. & Bray, F. (2020). *Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians.* doi:10.3322/caac.21660
3. Jusuf A, Wibawanto A, Icksan AG, Syahruddin E, Juniarti, Endardjo S. Kanker Paru Bukan Sel Kecil : Pedoman Nasional untuk Diagnosis dan Penatalaksanaan di Indonesia. Perhimpunan Dokter Paru Indonesia. 2018.p.1-24
4. Wieskopf B, Demangeat C, Purohit A, et all. Cyfra 21-1 as a Biologic Marker of Non Small Cell Lung Cancer. Journal Chestnet, doi:10.1378/chest.108.1.163
5. Dimas, and Muhartono. 2021. “Tumor Biomarkers in Lung Cancer”. *Medical Profession Journal of Lampung* 11 (1):91-99. https://doi.org/10.53089/medula.v11i1.187.
6. Leclerc. Tumor Marker. Diagnosis & Monitoring of Cancer. Biomerieux. 2022.
7. Nabi E A, Gomaa N E, Zeid A A. Evaluation of Cyfra 21-1 as a Diagnostic Tool in Lung Cancer. Journal of Applied Sciences Research, 5(9); 1195-1201. 2009.
8. Molina R, Agusti C, Filella X, et al. Study of a new tumor marker, CYFRA 21-1, in malignant and non malignant diseases. Tumour Biol. 1994;15:318–325. doi: 10.1159/000217908.
9. Rasmin M, Jusuf A, Yunus F, et al. *Buku Ajar Pulmonologi Dan Kedokteran Respirasi*. Buku 2. UI Publishing; 2018.
10. Amin M, Winariani K, Hasan H, dkk. Buku Ajar Paru Edisi 1. Departemen/ SMF Pulmonologi dan Ilmu Kedokteran Respirasi Fakultas Kedokteran Universitas Airlangga RSUD Soetomo. 2019.

11. The American Cancer Society medical and editorial content team. About Lung Cancer. cancer.org. 1.800.227.2345.
12. Centers For Disease Control And Prevention. National Center For Health Statistics. CDC WONDER On-Line Database, Compiled from Compressed Mortality File 1999-2016 Series 20 No. 2V, 2017.
13. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Pedoman Pengendalian Risiko Kanker Paru. Kementrian Kesehatan RI. Jakarta. 2018. ISBN 978-602-416-378-5
14. NCCN Guideline for Patient. Lung Cancer Screening. 2020. Available online at NCCN.org/patients.
15. Sukardja IDG. Onkologi Klinik. Ahli bedah umum dan onkologi, Bagian Bedah Fakultas Kedokteran Airlangga. RSUD Dr. Soetomo Surabaya. ISBN 979-8007-85-9.
16. Jusuf Anwar. Dasar-Dasar Diagnosis Kanker Paru. Penerbit Universitas Indonesia. 2017.
17. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011 Dec;32(4):605-44. doi: 10.1016/j.ccm.2011.09.001. PMID: 22054876; PMCID: PMC3864624.
18. Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung cancer. Semin Intervent Radiol. 2013 Jun;30(2):93-8. doi: 10.1055/s-0033-1342949. PMID: 24436524; PMCID: PMC3709917.
19. Ikram A, Jumadi I, Nurokhim M, dkk. Safety Assessments For Supporting The Application Of Nuclear Technology In Indonesia And A Comprehensive Study On High Natural Radioactivity Area. 2020. DOI: http://dx.doi.org/10.17146/jfn.2020.14.2.6408
20. Amin M, Yunus F, Antariksa B, dkk. PPOK Diagnosis dan Penatalaksanaan. PDPI. Penerbit Universitas Indonesia. 2016.
21. Chaudhry G-e-S, Md Akim A, Sung YY and Sifzizul TMT (2022), Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics. Front. Pharmacol. 13:842376. doi: 10.3389/fphar.2022.842376
22. Sánchez-Ortega, M.; Carrera, A.C.; Garrido, A. Role of NRF2 in Lung Cancer. *Cells* 2021, *10*, 1879. https://doi.org/10.3390/cells10081879

23. Liu L, Teng J, Zhang L, Cong P, Yao Y, Sun G, Liu Z, Yu T, Liu M. The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer. Biomed Res Int. 2017;2017:2013989. doi: 10.1155/2017/2013989. Epub 2017 May 18. PMID: 28607926; PMCID: PMC5451759.
24. Seijo LM, Peled N, Ajona D, Boeri M, Field JK, Sozzi G, Pio R, Zulueta JJ, Spira A, Massion PP, Mazzone PJ, Montuenga LM. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. J Thorac Oncol. 2019 Mar;14(3):343-357. doi: 10.1016/j.jtho.2018.11.023. Epub 2018 Dec 4. PMID: 30529598; PMCID: PMC6494979.
25. Febriani A, Furqon A. Metastasis Kanker Paru. Jurnal Respirasi. Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. 2018. https://doi.org/10.20473/jr.v4-I.3.2018.94-101
26. Jose J, Sunil PM, Nirmal RM, et all. Cyfra 21-1 : an Overview. 2013. Oral & Maxillofacialis Pathology Journal. ISSN 0976-1225.
27. Douglas Hanahan. Hallmarks of Cancer: New Dimensions. American Association for Cancer Research.*Cancer Discov* (2022) 12 (1): 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059
28. Edelman MJ, Hodgson L, Rosenblatt PY, Christenson RH, Vokes EE, Wang X, Kratzke R. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol. 2012 Apr;7(4):649-54. doi: 10.1097/JTO.0b013e31824a8db0. PMID: 22425913; PMCID: PMC5541770.
29. Mehta A, Parkash A, Bhatia M. Cross-Sectional Study to Establish the Utility of Serum Tumor Markers in the Diagnosis of Lung Cancer. Asian Pac J Cancer Prev. 2021 Aug 1;22(8):2569-2576. doi: 10.31557/APJCP.2021.22.8.2569. PMID: 34452572; PMCID: PMC8629472.
30. Cremades MJ, Menéndez R, Pastor A, Llopis R, Aznar J. Diagnostic value of cytokeratin fragment 19 (CYFRA 21-1) in bronchoalveolar lavage fluid in lung cancer. Respir Med. 1998 May;92(5):766-71. doi: 10.1016/s0954-6111(98)90010-5. PMID: 9713638.

31. Pothal S, Patil KP, Manjhi R, Dutta P. Diagnostic efficacy of broncho-alveolar lavage carcino-embronic antigen in carcinoma of lung. J Family Med Prim Care. 2019 May;8(5):1725-1729. doi: 10.4103/jfmpc.jfmpc_119_19. PMID: 31198744; PMCID: PMC6559055.
32. Dal Bello, M.G., Filiberti, R.A., Alama, A. *et al.* The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. *J Transl Med* 17, 74 (2019). https://doi.org/10.1186/s12967-019-1828-0
33. Sone k, Oguri T, Nakao M, et all. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy. Anticancer Research 37: 935-940 (2017) doi:10.21873/anticanres.11402
34. Pujol JL, Molinier O, Ebert W, Daurès JP, Barlesi F, Buccheri G, Paesmans M, Quoix E, Moro-Sibilot D, Szturmowicz M, Bréchot JM, Muley T, Grenier J. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer. 2004 Jun 1;90(11):2097-105. doi: 10.1038/sj.bjc.6601851. PMID: 15150567; PMCID: PMC2409493.
35. Mustari, SM. Analisis Kadar Interleukin 6 Serum terhadap kesintasan pada pasien kanker paru karsinoma bukan sel kecil (KPKBSK) Stage Lanjut. Departemen Pulmonologi & Kedokteran Respirasi FK UNHAS. 2021.
36. Chewaskulyong B, Tanyakul P, Tantraworasin A. Serum CYFRA 21-1 and CEA Level as a Predicting Marker for Advanced Non Small Cell Cancer. Topic : Marker for Prognosis. Journal of Thoracic Oncology. 2016. DOI: https://doi.org/10.1016/j.jtho.2016.11.1129
37. Wieskopf B, Demangeat C, Purohit A, et all. Cyfra 21-1 as a Biologic Marker of Non Small Cell Lung Cancer. Journal Chestnet, doi:10.1378/chest.108.1.163
38. M Rapellino, J Niklinski, F Pecchio, M Furman, S Baldi, L Chyczewski, E Ruffini, E Chyczewska. CYFRA 21-1 as a Tumour Marker for Bronchogenic Carcinoma. European Respiratory Journal 1995 8: 407-410; DOI: 10.1183/09031936.95.08030407
39. Lucio Trevisani, Stefano Putinati, Sergio Sartori, Vincenzo Abbasciano, Bruno Bagni, Cytokeratin Tumor Marker Levels in Bronchial Washing in the

Diagnosis of Lung Cancer, Chest, Volume 109, Issue 1,1996, Pages 104-108, ISSN 0012-3692, https://doi.org/10.1378/chest.109.1.104.

40. Nyambe H. Perbandingan Kesintasan Pasien Kanker Paru Kelompok Bukan Sel Kecil yang Mendapat Terapi Target Epidermal Growth Factor Receptor-Tyrosin Kinase Inhibitor dan Yang Mendapat Kemoterapi Lini Pertama. Departemen Pulmonologi & Kedokteran Respirasi FK UNHAS. 2021.
41. Xing PY, Zhu YX, Wang L, Hui ZG, Liu SM, Ren JS, Zhang Y, Song Y, Liu CC, Huang YC, Liao XZ, Xing XJ, Wang DB, Yang L, Du LB, Liu YQ, Zhang YZ, Liu YY, Wei DH, Zhang K, Shi JF, Qiao YL, Chen WQ, Li JL, Dai M; LuCCRES Group. What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China. Cancer Med. 2019 Jul;8(8):4055-4069. doi: 10.1002/cam4.2256. Epub 2019 May 31. PMID: 31150167; PMCID: PMC6639195.
42. Ruano-Raviña A, Provencio M, Calvo de Juan V, Carcereny E, Moran T, Rodriguez-Abreu D, López-Castro R, Cuadrado Albite E, Guirado M, Gómez González L, Massutí B, Ortega Granados AL, Blasco A, Cobo M, Garcia-Campelo R, Bosch J, Trigo J, Juan Ó, Aguado de la Rosa C, Dómine M, Sala M, Oramas J, Casal-Rubio J, Cerezo S. Lung cancer symptoms at diagnosis: results of a nationwide registry study. ESMO Open. 2020 Nov;5(6):e001021. doi: 10.1136/esmoopen-2020-001021. PMID: 33214227; PMCID: PMC7678343.
43. Debieuvre D, Molinier O, Falchero L, Locher C, Templement-Grangerat D, Meyer N, Morel H, Duval Y, Asselain B, Letierce A, Trédaniel J, Auliac JB, Bylicki O, Moreau L, Fore M, Corre R, Couraud S, Cortot A; Study Group KBP-2020-CPHG; KBP-2020-CPHG. Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies. Lancet Reg Health Eur. 2022 Aug 29;22:100492. doi: 10.1016/j.lanepe.2022.100492. PMID: 36108315; PMCID: PMC9445429.
44. Yang CC, Liu CY, Wang KY, Wen FH, Lee YC, Chen ML. Smoking Status Among Patients With Newly Diagnosed Lung Cancer in Taiwan. J Nurs

Res. 2019 Aug;27(4):e32. doi: 10.1097/jnr.0000000000000293. PMID: 30395018; PMCID: PMC6641475.

45. Singh N, Aggarwal AN, Gupta D, Behera D, Jindal SK. Quantified smoking status and non-small cell lung cancer stage at presentation: analysis of a North Indian cohort and a systematic review of literature. J Thorac Dis. 2012 Oct;4(5):474-84. doi: 10.3978/j.issn.2072-1439.2012.05.11. PMID: 23050111; PMCID: PMC3461078.
46. Bangash NSA, Hashim N, Ismail NE. Smoking status affecting survival of adenocarcinoma lung cancer patients in Kuala Lumpur, Malaysia. 2017. Asian Journal of Pharmaceutical and Clinical Research 10(9):312. DOI:10.22159/ajpcr.2017.v10i9.17147
47. Cukic V. The Association Between Lung Carcinoma and Tuberculosis. Med Arch. 2017 Jun;71(3):212-214. doi: 10.5455/medarh.2017.71.212-214. PMID: 28974836; PMCID: PMC5585804.
48. Bhowmik S, Mohanto NC, Sarker D, Sorove AA. Incidence and Risk of Lung Cancer in Tuberculosis Patients, and Vice Versa: A Literature Review of the Last Decade. Biomed Res Int. 2022 Dec 19;2022:1702819. doi: 10.1155/2022/1702819. PMID: 36578803; PMCID: PMC9792248.
49. Sugiharto S, Simanjuntak RAPS, Lariss O. Kanker Paru, Faktor Resiko dan Pencegahannya. November 2021. DOI:10.24912/psenapenmas.v0i0.15060
50. Soeroso, Noni Novisari. Ananda, Fannie Rizki. Lung Cancer Among Never-Smoker Women : An Epidemiological Data In North Sumatera, Indonesia. Published 2019.
51. Fawziah A, Sari NK, Uyainah A. Kesintasan Satu Tahun Penderita Karsinoma Paru Bukan Sel Kecil Stadium IIIB/ IV Usia Lanjut yang Menjalani Kemoterapi Dibandingkan dengan Non-Kemoterapi. Indonesian Journal of Critial and Emergency Medicine. 2015.
52. Xueli Zhang, Yamin Liu, Hua Shao, Xiao Zheng, Obesity Paradox in Lung Cancer Prognosis: Evolving Biological Insights and Clinical Implications, Journal of Thoracic Oncology, Volume 12, Issue 10, 2017, Pages 1478-1488, ISSN 1556-0864, https://doi.org/10.1016/j.jtho.2017.07.022.
53. Tatun, Rosa, et al. "Gambaran CT Scan Toraks Sesuai dengan Jenis Sitologi/Histologi pada Pasien Kanker Paru yang Merokok." *eJournal*

Kedokteran Indonesia, vol. 3, no. 3, 28 Dec. 2015, doi:10.23886/ejki.3.5645..

54. Sabria, Chairunnisa Rosadi (2021) Karakteristik Gambaran CT-Scan Pasien Adenokarsinoma Paru dengan Status Mutasi EGFR di SUP Dr. M. Djamil Padang Periode 1 Januari 2018 - 31 Desember 2019. Diploma thesis, Universitas Andalas.
55. Shinagawa N. A review of existing and new methods of bronchoscopic diagnosis of lung cancer. Respir Investig. 2019 Jan;57(1):3-8. doi: 10.1016/j.resinv.2018.08.004. Epub 2018 Oct 22. PMID: 30361052.
56. Lee P, Colt HG. Bronchoscopy in lung cancer: appraisal of current technology and for the future. J Thorac Oncol. 2010 Aug;5(8):1290-300. doi: 10.1097/JTO.0b013e3181e41843. PMID: 20661089.
57. Putra MA, Iskandar MH. Karakteristik Penderita Kanker Paru di Rumah Sakit Wahidin Sudirohusodo Makassar Periode Januari – Desember 2016. FK UNHAS. 2017.
58. Ching-Yao Yang, Yen-Ting Lin, Li-Ju Lin, Ya-Hsuan Chang, Hsuan-Yu Chen, Yi-Pin Wang, Jin-Yuan Shih, Chong-Jen Yu, Pan-Chyr Yang, Stage Shift Improves Lung Cancer Survival: Real-World Evidence, Journal of Thoracic Oncology, Volume 18, Issue 1, 2023, Pages 47-56, ISSN 1556-0864, https://doi.org/10.1016/j.jtho.2022.09.005.
59. Kerrigan K, Wang X, Haaland B, Adamson B, Patel S, Puri S, Akerley W. Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status. Clin Lung Cancer. 2021 Jul;22(4):260-267.e2. doi: 10.1016/j.cllc.2021.01.013. Epub 2021 Jan 26. PMID: 33678584.
60. Bhatti V, Kwatra KS, Puri S, Calton N. Histopathological Spectrum and Immunohistochemical Profile of Lung Carcinomas: A 9-Year Study from a Tertiary Hospital in North India. Int J Appl Basic Med Res. 2019 Jul-Sep;9(3):169-175. doi: 10.4103/ijabmr.IJABMR_66_19. PMID: 31392181; PMCID: PMC6652278.
61. PRADNYAANDARA, I Gusti Bagus Mulia Agung et al. Karakteristik Pasien Karsinoma Paru Di Rsup Sanglah Denpasar Tahun 2017-2018. E-Jurnal Medika Udayana, [S.l.], v. 9, n. 11, p. 43-48, nov. 2020. ISSN 2303-1395. Available at: <https://ojs.unud.ac.id/index.php/eum/article/view/67777>.

Date accessed: 06 may 2023. doi: https://doi.org/10.24843/MU.2020.V09.i11.P07.

62. Zheng M. Classification and Pathology of Lung Cancer. Surg Oncol Clin N Am. 2016 Jul;25(3):447-68. doi: 10.1016/j.soc.2016.02.003. PMID: 27261908.
63. Barta JA, Powell CA, Wisnivesky JP. Global Epidemiology of Lung Cancer. Ann Glob Health. 2019 Jan 22;85(1):8. doi: 10.5334/aogh.2419. PMID: 30741509; PMCID: PMC6724220.
64. Song MA, Benowitz NL, Berman M, Brasky TM, Cummings KM, Hatsukami DK, Marian C, O'Connor R, Rees VW, Woroszylo C, Shields PG. Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma. J Natl Cancer Inst. 2017 Dec 1;109(12):djx075. doi: 10.1093/jnci/djx075. PMID: 28525914; PMCID: PMC6059254.
65. Chyczewski L, Nikliński J, Chyczewska E, Laudański J, Furman M. Immunohistochemical analysis of tissue localization of cytokeratin 19 in lung cancer. Rocz Akad Med Bialymst. 1997;42 Suppl 1:162-72. PMID: 9337534.
66. Ebert W, Dienemann H, Fateh-Moghadam A, Scheulen M, Konietzko N, Schleich T, Bombardieri E. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem. 1994 Mar;32(3):189-99. PMID: 7518259.
67. Garcia-Valdecasas Gayo, Sonsoles, Ruiz-Alvarez, Maria Jesus, Gonzalez-Gay, Daniel, Ramos-Corral, Raquel, Marquez-Lietor, Eva, Del Amo, Nazaret, Plata, Maria del Carmen, Guillén-Santos, Raquel, Arribas, Ignacio and Cava-Valenciano, Fernando. "CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value" *Advances in Laboratory Medicine / Avances en Medicina de Laboratorio*, vol. 1, no. 4, 2020, pp. 20200005. https://doi.org/10.1515/almed-2020-0005
68. Fletcher DA, Mullins RD. Cell mechanics and the cytoskeleton. Nature. 2010 Jan 28;463(7280):485-92. doi: 10.1038/nature08908. PMID: 20110992; PMCID: PMC2851742.

69. Liu L, Xie W, Xue P, Wei Z, Liang X, Chen N. Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis. PLoS One. 2019 May 9;14(5):e0216561. doi: 10.1371/journal.pone.0216561. PMID: 31071161; PMCID: PMC6508679.
70. Oachim Schneider, Tumor Markers in Detection of Lung Cancer, Advances in Clinical Chemistry, Elsevier, Volume 42, 2006, Pages 1-41, ISSN 0065-2423, ISBN 9780120103423, https://doi.org/10.1016/S0065-2423(06)42001-1.
71. Sertić Milić H, Franjević A, Bubanović G, et all. Size, edge, and stage of KPKBSK determine the release of CYFRA 21-1 in bloodstream. Wien Klin Wochenschr. 2015;127 : 465–471. doi: 10.1007/s00508-014-0678-2.